Information  X 
Enter a valid email address

Synairgen swings to H1 pretax loss

By BFN News | 07:39 AM | Wednesday 16 September, 2015

Synairgen has swung to an H1 pretax loss of £1.0m, from a prior same period profit of £1.9m. Revenue was £25,000, from £4.25m. CEO Richard Marsden commented: "During the period, Synairgen has been focused on working with AstraZeneca to support the start of the Phase IIa trial in AZD9412, which has now commenced and we look forward to updating you with the results. "We have also devoted significant resource to assessing and bringing new programmes into the company and we are delighted to have achieved the first of these, the recently announced collaboration with Pharmaxis in the important indication of Idiopathic Pulmonary Fibrosis." Story provided by

a d v e r t i s e m e n t